Single infusion of Lilly gene editing cuts cholesterol with the company planning long-term study

A single intravenous infusion of Lilly's investigational base editor VERVE‑102 produced dose-dependent reductions in PCSK9 of up to 88 per cent and LDL cholesterol of up to 62 per cent, with effects sustained for up to 18 months. …